1. Academic Validation
  2. Development and Profiling of Inverse Agonist Tools for the Neuroprotective Transcription Factor Nurr1

Development and Profiling of Inverse Agonist Tools for the Neuroprotective Transcription Factor Nurr1

  • J Med Chem. 2021 Oct 28;64(20):15126-15140. doi: 10.1021/acs.jmedchem.1c01077.
Daniel Zaienne 1 Sabine Willems 1 Simone Schierle 1 Jan Heering 2 Daniel Merk 1 3
Affiliations

Affiliations

  • 1 Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, D-60438 Frankfurt, Germany.
  • 2 Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, D-60596 Frankfurt, Germany.
  • 3 Department of Pharmacy, Ludwig-Maximilians-Universität München, D-81377 Munich, Germany.
Abstract

The ligand-sensing transcription factor nuclear receptor related 1 (Nurr1) evolves as an appealing target to treat neurodegenerative diseases. Despite its therapeutic potential observed in various rodent models, potent modulators for Nurr1 are lacking as pharmacological tools. Here, we report the structure-activity relationship and systematic optimization of indole-based inverse Nurr1 agonists. Optimized analogues decreased the receptor's intrinsic transcriptional activity by up to more than 90% and revealed preference for inhibiting Nurr1 monomer activity. In orthogonal cell-free settings, we detected displacement of NCoRs and disruption of the Nurr1 homodimer as molecular modes of action. The inverse Nurr1 agonists reduced the expression of Nurr1-regulated genes in T98G cells, and treatment with an inverse Nurr1 agonist mimicked the effect of Nurr1 silencing on interleukin-6 release from LPS-stimulated human astrocytes. The indole-based inverse Nurr1 agonists valuably extend the toolbox of Nurr1 modulators to further probe the role of Nurr1 in neuroinflammation, Cancer, and beyond.

Figures
Products